Hansoh Pharma's HS-20093 Drug Gets Another Breakthrough Therapy Designation in China

MT Newswires Live

Apr 18, 2025

Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.

This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.

HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.

Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2528320460"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528320460\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2528320460?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-18 16:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528320460","market":"hk","top_or_hot":-1,"title":"Hansoh Pharma's HS-20093 Drug Gets Another Breakthrough Therapy Designation in China","media":"MT Newswires Live","content":"<html><body><p> Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.</p><p>This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.</p><p>HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.</p><p>Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's HS-20093 Drug Gets Another Breakthrough Therapy Designation in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's HS-20093 Drug Gets Another Breakthrough Therapy Designation in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-18 16:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.</p><p>This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.</p><p>HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.</p><p>Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2528320460","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528320460","pubTimestamp":1744964786,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.This new designa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药"},"translate_title":"翰森制药HS-20093药物在中国再获突破性疗法认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharmaceutical Group's (HKG:3692) antibody-drug conjugate HS-20093 received another breakthrough therapy designation (BTD) from China's National Medical Products Administration.This new designation aims to benefit HS-20093's development as a treatment for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, which has progressed or recurred following platinum-based chemotherapy.HS-20093 was previously granted BTDs for extensive-stage small-cell lung cancer that developed after standard first-line treatment and for osteosarcoma in patients with disease progression after at least two prior lines of therapy, according to a Thursday filing with the Hong Kong Exchange.Drug candidates with BTD status gain advantages like potential conditional approval and priority review, accelerating their development for serious diseases with limited treatment options.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}